Preformulation Studies of a Stable PTEN-PDZ Lipopeptide Able to Cross an In Vitro Blood-Brain-Barrier Model As a Potential Therapy for Alzheimer's Disease

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2020 Sep 5

PMID 32888078

Citations 3

Authors

Aikaterini Lalatsa

Yujiao Sun

Jose Ignacio Gamboa

Shira Knafo

Affiliations

Soon will be listed here.

Abstract

Purpose: Amyloid β (Aβ) drives the accumulation of excess Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) at synapses, inducing synaptic depression and perturbing memory. This recruitment of PTEN to synapses in response to Aβ drives its interaction with PSD95/Disc large/Zonula occludens-1 (PDZ) proteins and, indeed, we previously showed that an oligo lipopeptide (PTEN-PDZ) capable of blocking such PTEN:PDZ interactions rescues the synaptic and cognitive deficits in a mouse model of Alzheimer's disease. Hence, the PTEN:PDZ interaction appears to be crucial for Aβ-induced synaptic and cognitive impairment. Here we have evaluated the feasibility of using PTEN-PDZ lipopeptides based on the human/mouse PTEN C-terminal sequence, testing their stability in biological fluids, their cytotoxicity, their ability to self-assemble and their in vitro blood-brain barrier (BBB) permeability. Myristoyl or Lauryl tails were added to the peptides to enhance their cell permeability.

Methods: Lipopeptides self assembly was assessed using electron microscopy and the thioflavin T assay. Stability studies in mouse plasma (50%), intestinal washing, brain and liver homogenates as well as permeability studies across an all human 2D blood-brain barrier model prepared with human cerebral endothelial cells (hCMEC/D3) and human astrocytes (SC-1800) were undertaken.

Results: The mouse lauryl peptide displayed enhanced overall stability in plasma, ensuring a longer half-life in circulation that meant there were larger amounts available for transport across the BBB (Papp: 6.28 ± 1.85 × 10 cm s).

Conclusion: This increased availability, coupled to adequate BBB permeability, makes this peptide a good candidate for therapeutic parenteral (intravenous, intramuscular) administration and nose-to-brain delivery. Graphical Abstract.

Citing Articles

Biomarker profiling to determine clinical impact of microRNAs in cognitive disorders.

Zhai W, Zhao M, Wei C, Zhang G, Qi Y, Zhao A Sci Rep. 2024; 14(1):8270.

PMID: 38594359 PMC: 11004146. DOI: 10.1038/s41598-024-58882-2.

Malignant Brain Aging: The Formidable Link Between Dysregulated Signaling Through Mechanistic Target of Rapamycin Pathways and Alzheimer's Disease (Type 3 Diabetes).

de la Monte S J Alzheimers Dis. 2023; 95(4):1301-1337.

PMID: 37718817 PMC: 10896181. DOI: 10.3233/JAD-230555.

Aberrant Synaptic PTEN in Symptomatic Alzheimer's Patients May Link Synaptic Depression to Network Failure.

Diaz Gonzalez M, Buberman A, Morales M, Ferrer I, Knafo S Front Synaptic Neurosci. 2021; 13:683290.

PMID: 34045952 PMC: 8144462. DOI: 10.3389/fnsyn.2021.683290.

References

Ghosh A, Raju N, Tweedle M, Kumar K . In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells. Cancer Biother Radiopharm. 2017; 32(1):24-32. PMC: 5911699. DOI: 10.1089/cbr.2016.2136. View

Thorne R, Frey 2nd W . Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet. 2001; 40(12):907-46. DOI: 10.2165/00003088-200140120-00003. View

Sahagun G, Moore S, Hart M . Permeability of neutral vs. anionic dextrans in cultured brain microvascular endothelium. Am J Physiol. 1990; 259(1 Pt 2):H162-6. DOI: 10.1152/ajpheart.1990.259.1.H162. View

Patabendige A, Skinner R, Morgan L, Abbott N . A detailed method for preparation of a functional and flexible blood-brain barrier model using porcine brain endothelial cells. Brain Res. 2013; 1521:16-30. PMC: 3694295. DOI: 10.1016/j.brainres.2013.04.006. View

Lalatsa A, Schatzlein A, Mazza M, Le T, Uchegbu I . Amphiphilic poly(L-amino acids) - new materials for drug delivery. J Control Release. 2012; 161(2):523-36. DOI: 10.1016/j.jconrel.2012.04.046. View

Liederer B, Borchardt R . Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci. 2006; 95(6):1177-95. DOI: 10.1002/jps.20542. View

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

Opazo P, Watabe A, Grant S, ODell T . Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms. J Neurosci. 2003; 23(9):3679-88. PMC: 6742185. View

BenMohamed L, Krishnan R, Auge C, Primus J, Diamond D . Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology. 2002; 106(1):113-21. PMC: 1782698. DOI: 10.1046/j.1365-2567.2002.01396.x. View

10.

Peineau S, Taghibiglou C, Bradley C, Wong T, Liu L, Lu J . LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007; 53(5):703-17. DOI: 10.1016/j.neuron.2007.01.029. View

11.

Wu S, Campbell C, Koda Y, Blanchfield J, Toth I . Investigation of the route of absorption of lipid and sugar modified leu-enkephalin analogues and their enzymatic stability using the caco-2 cell monolayer system. Med Chem. 2006; 2(2):203-11. DOI: 10.2174/157340606776056205. View

12.

Lalatsa A, Schatzlein A, Uchegbu I . Strategies to deliver peptide drugs to the brain. Mol Pharm. 2014; 11(4):1081-93. DOI: 10.1021/mp400680d. View

13.

Lalatsa A, Lee V, Malkinson J, Zloh M, Schatzlein A, Uchegbu I . A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol Pharm. 2012; 9(6):1665-80. DOI: 10.1021/mp300009u. View

14.

Dubey R, McALLISTER C, Inoue M, Wilkinson G . Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. J Clin Invest. 1989; 84(4):1155-9. PMC: 329772. DOI: 10.1172/JCI114279. View

15.

Dewji N, Azar M, Hanson L, Frey Ii W, Morimoto B, Johnson D . Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the Brain. J Alzheimers Dis Rep. 2018; 2(1):169-179. PMC: 6218153. DOI: 10.3233/ADR-180078. View

16.

Serrano Lopez D, Lalatsa A . Peptide pills for brain diseases? Reality and future perspectives. Ther Deliv. 2013; 4(4):479-501. DOI: 10.4155/tde.13.5. View

17.

Knafo S, Sanchez-Puelles C, Palomer E, Delgado I, Draffin J, Mingo J . PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. Nat Neurosci. 2016; 19(3):443-53. DOI: 10.1038/nn.4225. View

18.

Goodwin D, Varamini P, Simerska P, Toth I . Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides. Pharm Res. 2014; 32(5):1570-84. DOI: 10.1007/s11095-014-1558-1. View

19.

Lalatsa A, Schatzlein A, Garrett N, Moger J, Briggs M, Godfrey L . Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration. J Control Release. 2014; 197:87-96. DOI: 10.1016/j.jconrel.2014.10.028. View

20.

Wolff A, Antfolk M, Brodin B, Tenje M . In Vitro Blood-Brain Barrier Models-An Overview of Established Models and New Microfluidic Approaches. J Pharm Sci. 2015; 104(9):2727-46. DOI: 10.1002/jps.24329. View